In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).
Saved in:
| Title: | In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). |
|---|---|
| Authors: | Kurmasheva RT; Greehey Children's Cancer Research Institute, San Antonio, Texas, USA., Erickson SW; RTI International, Research Triangle Park, North Carolina, USA., Han R; Salarius Pharmaceuticals, Salt Lake City, Utah, USA., Teicher BA; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Smith MA; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Roth M; Pediatrics, Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gorlick R; Pediatrics, Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houghton PJ; Greehey Children's Cancer Research Institute, San Antonio, Texas, USA. |
| Source: | Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Nov; Vol. 68 (11), pp. e29304. Date of Electronic Publication: 2021 Aug 28. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
